Strategies for therapeutic targeting of the Aldosterone-Mineralocorticoid Receptor signaling pathway
Final Report Abstract
The scientific network ‘Strategies for therapeutic targeting of the Aldosterone-Mineralocorticoid Receptor signaling pathway’ (ADMIRE network) represents an international consortium of researchers from a broad range of backgrounds interested in aldosterone and the mineralocorticoid receptor (MR). MR is a ligand-activated transcription factor and an established target for the pharmacological treatment of cardiovascular disease. The aims of this network were to strengthen the scientific interaction between researchers in basic, translational, and clinical science, to provide training opportunities for early stage researchers in the field, and to develop a roadmap for the investigation of therapeutic targeting of the aldosterone-MR signaling pathway in a broader range of organ systems and diseases. The ADMIRE network organized four meetings for scientific exchange and strategic discussions, which have been very successful in strengthening the European research community in the field. Topics covered basic science, emerging fields of indications for MR antagonists, and new pharmacological approaches including recently developed non-steroidal MR antagonists, aldosterone synthase inhibitors, and epigenetic drugs. The participants discussed possibilities, advantages and disadvantages of forming a training network for early stage researchers within EU funding frames. As a result, the ADMIRE network decided to further explore the possibility to apply for a European Cooperation in Science and Technology (COST) action. To create an opportunity for continued scientific exchange and education of early stage researchers, the ADMIRE network implemented a virtual lecture series with expert speakers providing an overview on the state of the art in their respective field and discussing current data with the community, which is internationally recognized. As key output of the scientific discussions, the ADMIRE network released a roadmap editorial on ‘Emerging Fields for Therapeutic Targeting of the Aldosterone‐Mineralocorticoid Receptor Signaling Pathway’ and two focused review articles on the role of MR in cardiovascular disease and the molecular pharmacology of MR.
Publications
-
Emerging fields for therapeutic targeting of the aldosterone–mineralocorticoid receptor signaling pathway. British Journal of Pharmacology, 179(13), 3099-3102.
Lother, Achim; Jaisser, Frédéric & Wenzel, Ulrich O.
-
Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney International Supplements, 12(1), 19-26.
Bauersachs, Johann & Lother, Achim
-
Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators. Steroids, 199, 109291.
Koca, Duygu & Lother, Achim
